Andrey A Lysenko

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2504841/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia. Human Vaccines and Immunotherapeutics, 2017, 13, 613-620.	3.3	92
2	Formatted single-domain antibodies can protect mice against infection with influenza virus (H5N2). Antiviral Research, 2013, 97, 245-254.	4.1	35
3	Passive immunization with a recombinant adenovirus expressing an HA (H5)-specific single-domain antibody protects mice from lethal influenza infection. Antiviral Research, 2013, 97, 318-328.	4.1	35
4	Vaccination potential of B and T epitope-enriched NP and M2 against Influenza A viruses from different clades and hosts. PLoS ONE, 2018, 13, e0191574.	2.5	23
5	The differences in immunoadjuvant mechanisms of TLR3 and TLR4 agonists on the level of antigen-presenting cells during immunization with recombinant adenovirus vector. BMC Immunology, 2018, 19, 26.	2.2	7
6	Construction of recombinant adenoviral vector expressing genes of the conservative proteins M2 "ion channel―and nucleoprotein of influenza A virus. Molecular Genetics, Microbiology and Virology, 2014, 29, 69-76.	0.3	2
7	Human TRIM14 protects transgenic mice from influenza A viral infection without activation of other innate immunity pathways. Genes and Immunity, 2021, 22, 56-63.	4.1	2
8	Protecting Mice from H7 Avian Influenza Virus by Immunisation with a Recombinant Adenovirus Encoding Influenza A Virus Conserved Antigens. BIOpreparations Prevention Diagnosis Treatment, 2020, 20, 60-67.	0.5	1
9	A Study of the Immunogenicity and Protective Properties of Recombinant Influenza Vaccine. Molecular Genetics, Microbiology and Virology, 2020, 35, 159-167.	0.3	Ο